BRIEF-Kiniksa Pharmaceuticals Q3 EPS USD 0.25
Oct 28 (Reuters) - Kiniksa Pharmaceuticals Q3 operating expenses USD 156.834 million.
- Q3 net income USD 18.435 million
- Q3 pretax profit USD 27.157 million
- Q3 product revenue USD 180.855 million
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments